Article
Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Jun 2020
Craig Jeffrey W, Hasserjian Robert P, Kim Annette S, Aster Jon C, Pinkus Geraldine S, Hornick Jason L, Steensma David P, Coleman Lindsley R, DeAngelo Daniel J, Morgan Elizabeth A
Abstract excerpt
Greater than 90% of cases of systemic mastocytosis (SM) harbor pathogenic KIT mutations, particularly KITD816V. Prognostically-significant pathogenic KIT mutations also occur in 30-40% of core binding factor-associated acute myeloid leukemia (CBF-AML), but are uncommonly associated with concurrent SM. By comparison, the occurrence of SM in other myeloid neoplasms bearing pathogenic KIT mutations, particularly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
